Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2017

01-12-2017 | ORIGINAL ARTICLE

1,6-O,O-Diacetylbritannilactone Inhibits Eotaxin-1 and ALOX15 Expression Through Inactivation of STAT6 in A549 Cells

Authors: Xi Chen, Ning Ji, Nan Qin, Sheng-an Tang, Ran Wang, Yuling Qiu, Hongquan Duan, Dexin Kong, Meihua Jin

Published in: Inflammation | Issue 6/2017

Login to get access

Abstract

1,6-O,O-Diacetylbritannilactone (OODBL), a plant sesquiterpene lactone, was previously reported to show multiple pharmacological effects such as anti-cancer and anti-inflammatory activities. In this study, we investigated the anti-inflammatory effect of OODBL on interleukin (IL)-4-induced signal transducer and activator of transcription 6 (STAT6) signaling pathway in human lung A549 cells. We found that OODBL dramatically inhibited IL-4-induced messenger RNA (mRNA) expression of eotaxin-1 and arachidonate 15-lipoxygenase-1 (ALOX15) in a dose-dependent manner. To clarify the action mechanism of OODBL, we examined the effect of OODBL on activation of STAT6. OODBL decreased both STAT6 phosphorylation and reporter gene activity. Furthermore, OODBL suppressed phosphorylation of Janus Kinase 3 (JAK3) without affecting JAK1. Taken together, OODBL abolished IL-4-induced eotaxin-1 and ALOX15 mRNA expressions by repressing the activation of STAT6 and JAK3. These results suggest that OODBL has a potential therapeutic efficacy on inflammatory diseases especially allergic airway disease as a lead compound.
Literature
1.
Holgate, S.T. 2002. Airway inflammation and remodeling in asthma: Current concepts. Molecular Biotechnology 22 (2): 179–189.CrossRefPubMed
2.
Maddox, L., and D.A. Schwartz. 2002. The pathophysiology of asthma. Annual Review of Medicine 53: 477–498.CrossRefPubMed
3.
Colavita, A. M., A. J. Reinach, and S. P. Peters. 2000. Contributing factors to the pathobiology of asthma. The Th1/Th2 paradigm. Clinics in Chest Medicine 21 (2):263–277, viii.
4.
Garcia-Zepeda, E.A., M.E. Rothenberg, R.T. Ownbey, J. Celestin, P. Leder, and A.D. Luster. 1996. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Medicine 2 (4): 449–456.CrossRefPubMed
5.
Pease, J.E., and T.J. Williams. 2001. Eotaxin and asthma. Current Opinion in Pharmacology 1 (3): 248–253.CrossRefPubMed
6.
Niimi, A. 2013. Cough, asthma, and cysteinyl-leukotrienes. Pulmonary Pharmacology & Therapeutics 26 (5): 514–519.CrossRef
7.
O’Bryan, L., P. Pinkston, V. Kumaraswami, V. Vijayan, G. Yenokida, H.F. Rosenberg, R. Crystal, E.A. Ottesen, and T.B. Nutman. 2003. Localized eosinophil degranulation mediates disease in tropical pulmonary eosinophilia. Infection and Immunity 71 (3): 1337–1342.CrossRefPubMedPubMedCentral
8.
Siracusa, M. C., B. S. Kim, J. M. Spergel, and D. Artis. 2013. Basophils and allergic inflammation. The Journal of Allergy and Clinical Immunology 132 (4):789–801; quiz 788.
9.
Matsukura, S., C. Stellato, J.R. Plitt, C. Bickel, K. Miura, S.N. Georas, V. Casolaro, and R.P. Schleimer. 1999. Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. Journal of Immunology 163 (12): 6876–6883.
10.
Hoeck, J., and M. Woisetschlager. 2001. STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. Journal of Immunology 166 (7): 4507–4515.CrossRef
11.
Kuperman, D.A., and R.P. Schleimer. 2008. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Current Molecular Medicine 8 (5): 384–392.CrossRefPubMedPubMedCentral
12.
Kuhn, H., and V.B. O'Donnell. 2006. Inflammation and immune regulation by 12/15-lipoxygenases. Progress in Lipid Research 45 (4): 334–356.CrossRefPubMed
13.
Chu, H.W., S. Balzar, J.Y. Westcott, J.B. Trudeau, Y. Sun, D.J. Conrad, and S.E. Wenzel. 2002. Expression and activation of 15-lipoxygenase pathway in severe asthma: Relationship to eosinophilic phenotype and collagen deposition. Clinical and Experimental Allergy 32 (11): 1558–1565.CrossRefPubMed
14.
Liu, C., D. Xu, L. Liu, F. Schain, A. Brunnstrom, M. Bjorkholm, H.E. Claesson, and J. Sjoberg. 2009. 15-Lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 297 (1): L196–L203.CrossRefPubMed
15.
Zhao, J., B. Maskrey, S. Balzar, K. Chibana, A. Mustovich, H. Hu, J.B. Trudeau, V. O'Donnell, and S.E. Wenzel. 2009. Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine 179 (9): 782–790.CrossRefPubMedPubMedCentral
16.
Andersson, C.K., H.E. Claesson, K. Rydell-Tormanen, S. Swedmark, A. Hallgren, and J.S. Erjefalt. 2008. Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and remodeling. American Journal of Respiratory Cell and Molecular Biology 39 (6): 648–656.CrossRefPubMed
17.
Heydeck, D., L. Thomas, K. Schnurr, F. Trebus, W.E. Thierfelder, J.N. Ihle, and H. Kuhn. 1998. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: Evidence for the involvement of transcription factor STAT6. Blood 92 (7): 2503–2510.PubMed
18.
Conrad, D.J., and M. Lu. 2000. Regulation of human 12/15-lipoxygenase by Stat 6-dependent transcription. American Journal of Respiratory Cell and Molecular Biology 22 (2): 226–234.CrossRefPubMed
19.
Hoshino, A., T. Tsuji, J. Matsuzaki, T. Jinushi, S. Ashino, T. Teramura, K. Chamoto, et al. 2004. STAT6-mediated signaling in Th2-dependent allergic asthma: Critical role for the development of eosinophilia, airway hyper-responsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. International Immunology 16 (10): 1497–1505.CrossRefPubMed
20.
Vale, K. 2016. Targeting the JAK-STAT pathway in the treatment of ‘Th2-high’ severe asthma. Future Medicinal Chemistry 8 (4): 405–419.CrossRefPubMed
21.
Murata, T., N.I. Obiri, and R.K. Puri. 1998. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). International Journal of Molecular Medicine 1 (3): 551–557.PubMed
22.
Kelly-Welch, A.E., E.M. Hanson, M.R. Boothby, and A.D. Keegan. 2003. Interleukin-4 and interleukin-13 signaling connections maps. Science 300 (5625): 1527–1528.CrossRefPubMed
23.
24.
Whan Han, J., B. Gon Lee, Y. Kee Kim, J. Woo Yoon, H. Kyoung Jin, S. Hong, H. Young Lee, K. Ro Lee, and H. Woo Lee. 2001. Ergolide, sesquiterpene lactone from Inula britannica, inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-kappa B. British Journal of Pharmacology 133 (4): 503–512.CrossRefPubMedPubMedCentral
25.
Khan, A.L., J. Hussain, M. Hamayun, S.A. Gilani, S. Ahmad, G. Rehman, Y.H. Kim, S.M. Kang, and I.J. Lee. 2010. Secondary metabolites from Inula britannica L. and their biological activities. Molecules 15 (3): 1562–1577.CrossRefPubMed
26.
Tang, S.A., H. Zhu, N. Qin, J.Y. Zhou, E. Lee, D.X. Kong, M.H. Jin, and H.Q. Duan. 2014. Anti-inflammatory terpenes from flowers of Inula japonica. Planta Medica 80 (7): 583–589.CrossRefPubMed
27.
Pan, M.H., Y.S. Chiou, A.C. Cheng, N. Bai, C.Y. Lo, D. Tan, and C.T. Ho. 2007. Involvement of MAPK, Bcl-2 family, cytochrome c, and caspases in induction of apoptosis by 1, 6-O,O-diacetylbritannilactone in human leukemia cells. Molecular Nutrition & Food Research 51 (2): 229–238.CrossRef
28.
Liu, Y.P., J.K. Wen, Y.B. Wu, J. Zhang, B. Zheng, D.Q. Zhang, and M. Han. 2009. 1, 6-O,O-diacetylbritannilactones inhibits Ikappa B kinase beta-dependent NF-kappa B activation. Phytomedicine 16 (2–3): 156–160.CrossRefPubMed
29.
Rafi, M.M., N.S. Bai, Ho Chi Tang, R.T. Rosen, E. White, D. Perez, and R.S. Dipaola. 2005. A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Research 25 (1a): 313–318.PubMed
30.
Chen, X., S.A. Tang, E. Lee, Y. Qiu, R. Wang, H.Q. Duan, S. Dan, M. Jin, and D. Kong. 2015. IVSE, isolated from Inula japonica, suppresses LPS-induced NO production via NF-kappa B and MAPK inactivation in RAW264.7 cells. Life Sciences 124: 8–15.CrossRefPubMed
31.
Garcia, G., V. Godot, and M. Humbert. 2005. New chemokine targets for asthma therapy. Current Allergy and Asthma Reports 5 (2): 155–160.CrossRefPubMed
32.
Kuhn, H., S. Banthiya, and K. van Leyen. 2015. Mammalian lipoxygenases and their biological relevance. Biochimica et Biophysica Acta 1851 (4): 308–330.CrossRefPubMed
33.
Lundstrom, S.L., J. Yang, H.J. Kallberg, S. Thunberg, G. Gafvelin, J.Z. Haeggstrom, R. Gronneberg, et al. 2012. Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation. PloS One 7 (3): e33780.CrossRefPubMedPubMedCentral
34.
Ono, E., H. Mita, M. Taniguchi, N. Higashi, M. Hasegawa, E. Miyazaki, T. Kumamoto, and K. Akiyama. 2009. Concentration of 14, 15-leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid. Clinical and Experimental Allergy 39 (9): 1348–1352.CrossRefPubMed
35.
Han, H., D. Xu, C. Liu, H.E. Claesson, M. Bjorkholm, and J. Sjoberg. 2014. Interleukin-4-mediated 15-lipoxygenase-1 trans-activation requires UTX recruitment and H3K27me3 demethylation at the promoter in A549 cells. PloS One 9 (1): e85085.CrossRefPubMedPubMedCentral
36.
Chen, X.H., B.K. Patel, L.M. Wang, M. Frankel, N. Ellmore, R.A. Flavell, W.J. LaRochelle, and J.H. Pierce. 1997. Jak 1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat 6 signaling molecules. The Journal of Biological Chemistry 272 (10): 6556–6560.CrossRefPubMed
37.
Oakes, S.A., F. Candotti, J.A. Johnston, Y.Q. Chen, J.J. Ryan, N. Taylor, X. Liu, et al. 1996. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 5 (6): 605–615.CrossRefPubMed
38.
Mikita, T., D. Campbell, P. Wu, K. Williamson, and U. Schindler. 1996. Requirements for interleukin-4-induced gene expression and functional characterization of Stat 6. Molecular and Cellular Biology 16 (10): 5811–5820.CrossRefPubMedPubMedCentral
39.
Fruman, D.A., and G. Bismuth. 2009. Fine tuning the immune response with PI3K. Immunological Reviews 228 (1): 253–272.CrossRefPubMed
40.
Duan, W., A.M. Aguinaldo Datiles, B.P. Leung, C.J. Vlahos, and W.S. Wong. 2005. An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. International Immunopharmacology 5 (3): 495–502.CrossRefPubMed
41.
Lee, K.S., H.K. Lee, J.S. Hayflick, Y.C. Lee, and K.D. Puri. 2006. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. The FASEB Journal 20 (3): 455–465.CrossRefPubMed
42.
Doukas, J., L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, et al. 2009. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2, 4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. The Journal of Pharmacology and Experimental Therapeutics 328 (3): 758–765.CrossRefPubMed
43.
Hosokawa, Y., I. Hosokawa, S. Shindo, K. Ozaki, and T. Matsuo. 2016. IL-4 modulates CCL11 and CCL20 productions from IL-1beta-stimulated human periodontal ligament cells. Cellular Physiology and Biochemistry 38 (1): 153–159.CrossRefPubMed
44.
Wu, D., J. Zhou, H. Bi, L. Li, W. Gao, M. Huang, I.M. Adcock, P.J. Barnes, and X. Yao. 2014. CCL11 as a potential diagnostic marker for asthma? The Journal of Asthma 51 (8): 847–854.CrossRefPubMed
45.
Hogan, S.P. 2007. Recent advances in eosinophil biology. International Archives of Allergy and Immunology 143 (Suppl 1): 3–14.CrossRefPubMed
46.
Nakajima, H., and K. Takatsu. 2007. Role of cytokines in allergic airway inflammation. International Archives of Allergy and Immunology 142 (4): 265–273.CrossRefPubMed
47.
Jayawickreme, S.P., T. Gray, P. Nettesheim, and T. Eling. 1999. Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells. The American Journal of Physiology 276 (4 Pt 1): L596–L603.PubMed
48.
Shankaranarayanan, P., P. Chaitidis, H. Kuhn, and S. Nigam. 2001. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. The Journal of Biological Chemistry 276 (46): 42753–42760.CrossRefPubMed
49.
Chung, H.S., Y. Kim, S.J. Oh, H. Kim, S.I. Choi, Y. Zhang, J.H. Jeong, and H. Bae. 2013. A synthetic compound, 4-acetyl-3-methyl-6-(3,4,5-trimethoxyphenyl)pyrano[3,4-c]pyran-1,8-dione, ameliorates ovalbumin-induced asthma. Bioorganic & Medicinal Chemistry 21 (21): 6359–6365.CrossRef
50.
Hebenstreit, D., G. Wirnsberger, J. Horejs-Hoeck, and A. Duschl. 2006. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine & Growth Factor Reviews 17 (3): 173–188.CrossRef
51.
Oh, C.K., G.P. Geba, and N. Molfino. 2010. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. European Respiratory Review 19 (115): 46–54.CrossRefPubMed
52.
Cheng, C., W.E. Ho, F.Y. Goh, S.P. Guan, L.R. Kong, W.Q. Lai, B.P. Leung, and W.S. Wong. 2011. Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PloS One 6 (6): e20932.CrossRefPubMedPubMedCentral
Metadata
Title
1,6-O,O-Diacetylbritannilactone Inhibits Eotaxin-1 and ALOX15 Expression Through Inactivation of STAT6 in A549 Cells
Authors
Xi Chen
Ning Ji
Nan Qin
Sheng-an Tang
Ran Wang
Yuling Qiu
Hongquan Duan
Dexin Kong
Meihua Jin
Publication date
01-12-2017
Publisher
Springer US
Published in
Inflammation / Issue 6/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0637-y

Other articles of this Issue 6/2017

Inflammation 6/2017 Go to the issue

ORIGINAL ARTICLE

Lipoxin A4 Attenuates Bronchopulmonary Dysplasia via Upregulation of Let-7c and Downregulation of TGF-β1 Signaling Pathway

ORIGINAL ARTICLE

The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines

ORIGINAL ARTICLE

Vacuolar Protein Sorting 4B (VPS4B) Regulates Apoptosis of Chondrocytes via p38 Mitogen-Activated Protein Kinases (MAPK) in Osteoarthritis

ORIGINAL ARTICLE

Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells

ORIGINAL ARTICLE

Experimental Periodontitis in the Potentialization of the Effects of Immobilism in the Skeletal Striated Muscle

ORIGINAL ARTICLE

Endothelial BMP4 Regulates Leukocyte Diapedesis and Promotes Inflammation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits